🇺🇸 FDA
Pipeline program

Darlifarnib

KO-2806-001

Phase 1 small_molecule active

Quick answer

Darlifarnib for Solid Tumors With HRAS Alterations is a Phase 1 program (small_molecule) at Kura Oncology with 1 ClinicalTrials.gov record(s).

Program details

Company
Kura Oncology
Indication
Solid Tumors With HRAS Alterations
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials